Study of the Symptomatic Effects of Nocturnal Sodium Oxybate in Parkinson's Disease
Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
Sleep wake disturbance is a common problem in Parkinson's disease patients and so far the
therapeutic possibilities for symptomatic relief are limited. Small, open-label studies
indicate that the use of Xyrem (gamma-hydroxybutyrate) might be of benefit in this situation.
This study is intended to show a beneficial effect of the study medication in a randomized
cross-over trial, that fulfills strict scientific criteria.